The Quantellect read.As of Nov 19, 2026, 9 active firms cover Astrana Health Inc: 9 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $37.00 to $65.00, a moderate spread. The average target of $49.33 sits 66% above the current $29.67. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 7 to 9 over recent months. On the fundamentals, the Street sees revenue growth near 26% this year and 9% next, consensus EPS building from about $0.88 next quarter toward $3.48 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 active firms
Buy
Strong Buy00%
Buy9100%
Neutral00%
Sell00%
Strong Sell00%
Based on 9 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$49.33
+66.3% upside
Average target across 9 active firms as of Nov 19, 2026 vs $29.67 current
Highest Target$65.00
Average Target$49.33
Lowest Target$37.00
Detailed analyst forecasts for ASTH
Showing 1–10 of 10 named analysts shown · 9 active firms in the rating projection
As of Nov 19, 2026, 9 of 9 active firms rate ASTH a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ASTH EPS & revenue forecast
EPS · NEXT QUARTER
$0.88
Range $0.88 – $0.88 · 1 analysts · +19% YoY
Next period, 1 analysts expect Astrana Health Inc to earn $0.88 a share (range $0.88 – $0.88), versus $0.74 a year earlier. Full-year consensus is $2.94, growing to $3.48 the year after.
REVENUE · NEXT QUARTER
$1.1B
Range $1.0B – $1.1B · 1 analysts · +7% YoY
Revenue is expected to reach $1.1B (range $1.0B – $1.1B), +7.0% year-over-year. Full-year consensus is $4.0B, rising to $4.4B next year.
Top analysts covering Astrana Health Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ASTH.
#1
Andrew Mok
Barclays · Rank #385
Buy
$53.00+78.6% to target
Overall win rate
39%
+ Follow
#2
David Larsen
BTIG
Buy
$65.00+119.1% to target
Coverage
—
+ Follow
#3
Jailendra Singh
Truist Securities
Buy
No targeton ASTH
Coverage
—
+ Follow
#4
MS
Matthew Shea
Needham
Buy
$41.00+38.2% to target
Coverage
—
+ Follow
#5
Ryan Langston
TD Cowen
Buy
$50.00+68.5% to target
Coverage
—
+ Follow
ASTH stock forecast FAQ
What is ASTH's average 12-month price target?+
The 9 active firms with a live target average $49.33 for Astrana Health Inc over the next 12 months, ranging from a $65.00 high to a $37.00 low, as of Nov 19, 2026.
Is ASTH stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 9 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ASTH?+
The Street-high target is $65.00 (BTIG), and the Street-low is $37.00 (Jefferies). The average of all 9 active-firm targets is $49.33.
How many active Wall Street firms cover ASTH?+
9 active firms have a recognized rating on Astrana Health Inc as of Nov 19, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ASTH?+
Among analysts who currently cover ASTH, Andrew Mok of Barclays has the strongest overall Quantellect track record (Rank #385). Their current call is Buy with a $53.00 target.
What is Astrana Health Inc's projected EPS for next quarter?+
The consensus estimate is $0.88 per share (range $0.88 – $0.88) across 1 analysts. Full-year EPS is projected at $2.94, rising to $3.48 the following year.
How much revenue is Astrana Health Inc expected to report next quarter?+
Consensus revenue is $1.1B (range $1.0B – $1.1B). Full-year revenue is projected at $4.0B, growing to $4.4B next year.
Have analysts been upgrading or downgrading ASTH lately?+
As of Nov 19, 2026, 9 of 9 active firms rate ASTH a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ASTH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.